{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:30:45Z","timestamp":1791048645618,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T00:00:00Z","timestamp":1138060800000},"content-version":"vor","delay-in-days":1333,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> We have studied the role of protein kinase A (PKA) in neoplastic transformation, apoptosis, and angiogenesis and its relationship with other signaling molecules, as a basis for developing novel therapeutic strategies. We demonstrated the involvement of PKA type I (PKA\u2010I) in the transduction of mitogenic signals from different sources and demonstrated functional and structural interactions between PKA\u2010I and the activated epidermal growth factor receptor (EGFR). We contributed to the identification and development of several selective inhibitors of PKA\u2010I, such as 8\u2010Cl\u2010cAMP and a hybrid DNA\/RNA antisense oligonucleotide of a novel class (AS\u2010PKA\u2010I) and of EGFR, including mAbC225 and ZD1839 (Iressa). All these agents have been investigated in cancer patients. We demonstrated the therapeutic potential of the combined blockade of PKA\u2010I and EGFR, reporting a synergistic antitumor effect when their inhibitors are used in combination. We have also shown that PKA\u2010I and EGFR inhibitors are able to cooperate with selected class of cytotoxic drugs and with ionizing radiation, causing a synergistic inhibition of tumor growth <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, accompanied by inhibition of expression of growth and angiogenic factors and by suppression of vessel production. Moreover, PKA\u2010I is implicated in a bcl\u20102\u2010dependent apoptotic pathway, and we have recently reported a cooperative antitumor and proapoptotic effect of AS\u2010PKA\u2010I in combination with an AS\u2010bcl\u20102. Finally, we have shown that AS\u2010PKA\u2010I also has antitumor and antiangiogenic effects following oral administration and that they can be greatly enhanced in combination with oral ZD1839 and oral taxanes.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2002.tb04332.x","type":"journal-article","created":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T18:29:42Z","timestamp":1247164182000},"page":"139-147","source":"Crossref","is-referenced-by-count":83,"title":["Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy"],"prefix":"10.1111","volume":"968","author":[{"given":"GIAMPAOLO","family":"TORTORA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FORTUNATO","family":"CIARDIELLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,24]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00166-9"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008390206250"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.139"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00682703"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118088"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.5.2011"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0695-528"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00043-6"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(96)01002-4"},{"key":"e_1_2_10_11_2","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1016\/S0021-9258(18)53386-X","article-title":"8\u2010Cl\u2010cAMP induces truncation and down\u2010regulation of the RI\u03b1 subunit and up\u2010regulation of the RII\u03b2 subunit of cAMP\u2010dependent protein kinase leading to type II holoenzyme\u2010dependent growth inhibition and differentiation of HL\u201060 leukemia cells","volume":"268","author":"Rohlff C.","year":"1993","journal-title":"J. Biol. Chem."},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910530315"},{"key":"e_1_2_10_13_2","first-page":"4123","article-title":"Overexpression of the RI\u03b1 regulatory subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8\u2010chloro\u2010cyclic adenosine 3\u2032, 5\u2032 monophosphate in Chinese hamster ovary cells","volume":"54","author":"North P.","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_10_14_2","first-page":"49","article-title":"The cAMP\u2010dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors","volume":"1","author":"Tortora G.","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<710::AID-IJC18>3.0.CO;2-4"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2001.5164"},{"key":"e_1_2_10_17_2","first-page":"5107","article-title":"Synergistic inhibition of growth and induction of apoptosis by 8\u2010chloro\u2010cAMP and paclitaxel or cisplatin in human cancer cells","volume":"57","author":"Tortora G.","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.23.12586"},{"key":"e_1_2_10_19_2","first-page":"2506","article-title":"Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production","volume":"6","author":"Tortora G.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.24.13989"},{"key":"e_1_2_10_21_2","first-page":"1259","article-title":"A safety and pharmacokinetic study of a mixed\u2010backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by 2\u2010hour infusions in patients with refractory solid tumors","volume":"6","author":"Chen H.X.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204082"},{"key":"e_1_2_10_24_2","first-page":"3233","article-title":"The RI\u03b1 subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells","volume":"9","author":"Tortora G.","year":"1994","journal-title":"Oncogene"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1200906"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)80502-2"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005909419828"},{"key":"e_1_2_10_28_2","first-page":"161","article-title":"Cooperative antiproliferative effects of 8\u2010Cl\u2010cAMP and 528 anti\u2010epidermal growth factor receptor monoclonal antibody on human cancer cells","volume":"1","author":"Ciardiello F.","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.23.1770"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.14.1087"},{"key":"e_1_2_10_31_2","first-page":"4770","article-title":"Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy","volume":"59","author":"Hahnfeldt P.","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.4.1.121"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.4.750"},{"key":"e_1_2_10_34_2","first-page":"1523","article-title":"Neutralizing antibodies against epidermal growth factor and erbB\u20102\/neu receptor tyrosine kinases down\u2010regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo","volume":"151","author":"Petit A.M.V.","year":"1997","journal-title":"Am. J. Pathol."},{"key":"e_1_2_10_35_2","first-page":"1459","article-title":"Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello F.","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_36_2","first-page":"439","article-title":"8\u2010Chloro\u2010cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer","volume":"3","author":"Bianco C.","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2941"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03207-4"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1812"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.6.3509"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi981402a"},{"key":"e_1_2_10_42_2","first-page":"2537","article-title":"Combined blockade of PKA and bcl\u20102 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis","volume":"7","author":"Tortora G.","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_43_2","first-page":"4343","article-title":"Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti\u2010epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide","volume":"6","author":"Bianco C.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_44_2","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD\u20101839 (Iressa), an EGFR\u2010selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello F.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_45_2","first-page":"875","article-title":"Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti\u2010epidermal growth factor\u2010receptor antibody on human breast cancer cell growth","volume":"5","author":"Tortora G.","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_46_2","first-page":"4156","article-title":"Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity","volume":"7","author":"Tortora G.","year":"2001","journal-title":"Clin. Cancer Res."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2002.tb04332.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2002.tb04332.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:06:52Z","timestamp":1695607612000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2002.tb04332.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1111\/j.1749-6632.2002.tb04332.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04332.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}